Here is the design of a clinical trial:

Official Title: Efficacy of an Asynchronous Telerehabilitation Programme in Post-COVID-19 Patients: a Feasibility Study

Included conditions:
- Coronavirus
- Fatigue
- Musculoskeletal Complication

Study Armgroups:
- {'label': 'Experimental Group', 'type': 'EXPERIMENTAL', 'description': 'Telerehabilitation asynchronous programme at home', 'interventionNames': ['Other: Asynchronous telerehabilitation programme']}
- {'label': 'Control Group', 'type': 'ACTIVE_COMPARATOR', 'description': 'Rehabilitation programme with an explanatory booklet at home', 'interventionNames': ['Other: Rehabilitation programme']}

Interventions:
- {'type': 'OTHER', 'name': 'Asynchronous telerehabilitation programme', 'description': 'Home-based physical rehabilitation programme using a telerehabilitation platform', 'armGroupLabels': ['Experimental Group']}
- {'type': 'OTHER', 'name': 'Rehabilitation programme', 'description': 'Home-based physical rehabilitation programme by means of an explanatory booklet', 'armGroupLabels': ['Control Group']}

Primary Outcomes:
- {'measure': 'Fatigue Severity Level', 'description': 'Change in fatigue severity level. Fatigue will be assessed with the Fatigue Severity Scale (FSS). The Fatigue Severity Scale is a self-reported scale composed of 9 items. Each item is rated from 1 to 7 (from 1=strongly disagree to 7=strongly agree). In the FSS, a mean of less than 4 points is considered to be no fatigue and more than 4 is considered to present fatigue. The higher the score, the greater the severity of fatigue.', 'timeFrame': 'Pre-intervention (day 1); after intervention (day 84); follow up 1 (3 months after intervention); follow up 2 (6 months after intervention).'}

Please estimate the sample size based on the assumption: 
Not explicitly stated in the provided paragraph.
Sample size calculation
          A sample size of 50 subjects will be required, 20 in each group, plus 10 in anticipation of future losses according to the recommendations for RCT pilot studies [95, 96].